Changes in Beneficial Ownership · 4
Cocrystal Pharma, Inc.
COCPNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-03
- Issuer
- Cocrystal Pharma, Inc.
- Issuer CIK
- 0001412486
- Trading symbol
- COCP
Reporting owner 1
- Name
- FROST PHILLIP MD ET AL
- Reporting owner CIK
- 0000898860
- Relationship
- Director · 10% owner
- Address
- 4400 BISCAYNE BLVD, MIAMI, FL, 33137-3227
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-03 | P · Form 4 | 75,000 | A | 0.9412[F1] | 1,983,551 | I | By Frost Gamma Investments Trust[F2] |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common Stock | 27,100[F3] | D |
Table key
- D
- Direct
Footnotes
- F1
- The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.87 to $0.9499, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence.↩ 1
- F2
- These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.↩ 1
- F3
- Includes shares of common stock issuable upon vesting of restricted stock units.↩ 1
Remarks
This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Signature 1
- Signed
- /s/ Phillip Frost, MD ET AL
- Date
- 2026-08-05
Company context
Cocrystal is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by coronavirus, influenza virus and norovirus.
Current securities
Recent company filings
- 10-Q filingNov 16, 2026
- SCHEDULE 13D/A - filed by OPKO HEALTH, INC. regarding Cocrystal Pharma, Inc.Nov 6, 2026
- Regulation FD DisclosureSep 9, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 18, 2026
- Regulation FD DisclosureAug 17, 2026